Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: biomachine56 who wrote (2174)	5/23/2013 11:21:30 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2344

>> BKM120 seems to have a wider range of toxicities, especially hyperglycemia << Thanks for mentioning that. I had also noticed that this (expected) hallmark of pi3k inhibition just isn't showing in 866 trials. And welcome to S.I.! I expect the CRC results to come in positive, objective response. Results due within five trading days. Also intrigued that Kirkman would suggest that analysts hit the prostate and glio trial posters at the meeting, that all data is not in the abstracts. Ticked off that Kirkman didn't walk in with at least a first blush nsclc cut for squamous, just because. :-) Best! Rick